Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-30T20:46:55.863Z Has data issue: false hasContentIssue false
  • English
  • Français

PS1 -125 Assessment of Function and Quality of Life in a Phase II Multi-Institutional Clinical Trial of Fractionated Simultaneous In-Field Boost Radiotherapy for Patients with 1-2 Brain Metastases

Published online by Cambridge University Press:  18 October 2016

G Bauman ,
S Yartsev ,
D Roberge ,
R. MacRae ,
W Roa ,
V Panet-Raymond ,
L Masucci ,
B Yaremko ,
D. D’Souza  and
D. Palma
...Show all authors
G Bauman*
Affiliation:
Division of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON
S Yartsev
Affiliation:
Division of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON
D Roberge
Affiliation:
Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, QC
R. MacRae
Affiliation:
Division of Radiation Oncology, University of Ottawa, Ottawa, ON
W Roa
Affiliation:
Department of Radiation Oncology, Cross Cancer Institute, Edmonton, AB
V Panet-Raymond
Affiliation:
Department of Radiation Oncology, McGill University Health Centre, Montreal, QC
L Masucci
Affiliation:
Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, QC
B Yaremko
Affiliation:
Division of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON
D. D’Souza
Affiliation:
Division of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON
D. Palma
Affiliation:
Division of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON
T. Sexton
Affiliation:
Division of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON
E. Yu
Affiliation:
Division of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON
J.R. Pantarotto
Affiliation:
Division of Radiation Oncology, University of Ottawa, Ottawa, ON
B. Ahmad
Affiliation:
Division of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON
B. Fisher
Affiliation:
Division of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON
A.R. Dar
Affiliation:
Division of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON
C. Lambert
Affiliation:
Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, QC
G. Pond
Affiliation:
Department of Oncology, Department of Oncology, McMaster University, Hamilton, ON
L. Stitt
Affiliation:
Division of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON
K.Y. Tay
Affiliation:
Department of Diagnostic Radiology, London Health Sciences Centre, London, ON
G. Rodrigues
Affiliation:
Division of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON
*
glenn.bauman@lhsc.on.ca
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We examined functional outcomes and quality of life of whole brain radiotherapy (WBRT) with integrated fractionated stereotactic radiotherapy boost (FSRT) for brain metastases treatment. Methods Eighty seven people with 1-3 brain metastases were enrolled on this Phase II trial of WBRT (30Gy/10)+simultaneous FSRT, (60Gy/10). Results Mean (Min-Max) baseline KPS, Mini Mental Status Exam (MMSE) and FACT-BR quality of life were 83 (70-100), 28 (21-30) and 143 (98-153). Lower baseline MMSE (but not KPS or FACT-Br) was associated with worse survival after adjusting for age, number of metastases, primary and extra-cranial disease status. Crude rates of deterioration (>10 points decrease from baseline for KPS and FACT-Br, MMSE fall to<27) ranged from 26-38% for KPS, 32-59% for FACT-Br and 0-16%for MMSE depending on the time-point assessed with higher rates generally noted at earlier time points (<6months post-treatment). Using a linear mixed models analysis, significant declines from baseline were noted for KPS and FACT-Br (largest effects at 6 weeks to 3 months) with no significant change in MMSE. Conclusions The effects on function and quality of life of this integrated treatment of WBRT+simultaneous FSRT were similar to other published series combining WBRT+SRS.

Type
Poster Viewing Sessions
Information
Canadian Journal of Neurological Sciences , Volume 43 , Supplement S4: ABSTRACTS: 17th Biennial Canadian Neuro-Oncology Meeting , October 2016 , pp. S8
Copyright
Copyright © The Canadian Journal of Neurological Sciences Inc. 2016